LDHC

Across TCGA pan-cancer cohorts, LDHC mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LDHC data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LDHC mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LDHC expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where LDHC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.864	0.391	.002	42	view →
LUAD	OS	Median	All	0.569	0.931	.012	17	view →
LSCC	OS	Tertile	II,III,IV	0.912	0.217	.024	13	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LDHC–HNSC (DFS)

Open the HNSC breakdown →